Slide 1: Siegfried delivers profitable growth and confirms outlook
Siegfried delivers profitable growth and confirms outlook Half-Year Results 2026 August 21, 2026
Slide 2: Safe harbor statement
Safe harbor statement This document is solely for use in connection with the presentation held by Siegfried Holding AG. It is furnished to you for your information only and you may not reproduce or redistribute it to any other person. No representation or warranty, express or implied, is made to, an
Slide 3: Key highlights H1 2026
Key highlights H1 2026 Siegfried delivers profitable growth and confirms outlook Net sales Core EBITDA margin Acquisition of new sites in US CHF 633 million 22.4% Value unlock on track + 4.8% in LC prior year: 21.6% High customer interest + 2.2% in CHF First product transfer to be completed in 2026
Slide 4: Financial update
Financial update 4 | H1 2026
Slide 5: Solid performance sets foundation for full-year delivery
Solid performance sets foundation for full-year delivery Seasonality more pronounced due to acquisition effect Net sales H1 2026 vs H1 2025 Currency split H1 2026 26% CHF million H1 2026 H1 2025 Change Drug Substances 431.1 413.8 +4.2% (+6.4% in LC) EUR Drug Products 201.9 205.8 -1.9% (+1.5% in LC)
Slide 6: Reconciliation for H1 2026
Reconciliation for H1 2026 From Swiss GAAP FER to core results CHFm Adjustments 150 140.7 1.4 142.0 – Reclassification of the current net interest for 140 non-Swiss pension plans (CHF +0.9m) EBITDA and (CHF-0.9m net profit ) 130 120 – Integration costs (CHF +0.4m) 110 – Taxes CHF -0.1 100 90.5 90 -5
Slide 7: Profitability further increased
Profitability further increased Increased profitability through operational excellence, portfolio optimization, and cost discipline CHF million H1 2026 H1 2025 Change (%) Comments Net sales 633.0 619.5 2.2% Cost of goods sold -462.3 -456.5 1.3% – Core gross profit further increased Core gross profit
Slide 8: Free cash flow remained positive despite acquisition related outflows
Free cash flow remained positive despite acquisition related outflows Increased net working capital reflects phasing of tax payments and addition of acquisition CHF million H1 2026 H1 2025 Change (%) Comments Operating cash flow before changes in NWC 133.3 147.9 -9.9% Change in NWC -39.6 1.7 – Lower
Slide 9: Capital allocation framework for long-term value creation
Capital allocation framework for long-term value creation While value-accretive M&A is always on, our near-term priorities focus on integration and value creation Value accretive M&A Dividends − M&A is always on Strong top- − Disciplined pay-out ratio line growth − Will continue to be very selective
Slide 10: Strategy execution and outlook
Strategy execution and outlook 16 | 10 H1 2026
Slide 11: Execution of our EVOLVE+ strategy strengthens our unique position
Execution of our EVOLVE+ strategy strengthens our unique position Global scale, dual-supply capabilities and beginning-to-end offering address customer needs and market trends Customer demands Siegfried’s unique positioning Supply chain resilience Global manufacturing network with amid geopolitical
Slide 12: Together with our newly acquired sites, we now operate the largest global small molecules drug substance CDMO network
Together with our newly acquired sites, we now operate the largest global small molecules drug substance CDMO network Pennsville Minden USA Germany Grafton Nantong USA China Athens Wilmington St. Vulbas Evionnaz Zofingen Westbury1 USA USA France Switzerland Switzerland Australia 18 | 12 1 Extraction
Slide 13: Immediate customer interest in our additional US production capacity
Immediate customer interest in our additional US production capacity Predominantly for established and new commercial products, supporting attractive volume potential Strong commercial momentum … ... from a diverse customer pipeline 5 Customer visits completed within the last 6 weeks 40% 6 Additiona
Slide 14: Fully focused on unlocking acquisition value through capacity optimization
Fully focused on unlocking acquisition value through capacity optimization Product transfers to free-up capacity for new exclusive business are progressing as planned Product transfers initiated and first transfer to be completed in 2026 Comments 2026 2027 2028 2030 New exclusive business – Gradual
Slide 15: Strategic technology upgrades on track to support future growth
Strategic technology upgrades on track to support future growth Our broad technology offering is key to attract new business, especially from small and mid-size pharma Drug substance Bridging Drug product development and technologies development and manufacturing manufacturing Recent strategic expan
Slide 16: On track to meet our full-year targets
On track to meet our full-year targets Delivering the EVOLVE+ strategy through disciplined execution Outlook 2026 confirmed1 Positive mid-term outlook confirmed Net sales: high-single-digit growth (LC) Continued profitable growth Stepwise expanding above market (excl. M&A) profitability Core EBITDA
Slide 17: Thank you for your attention
September 23, 2026 Baader Investment Conference, Munich September 24, 2026 UBS – Best of Switzerland Conference November 06, 2026 ZKB – Swiss Equity Thank you for Conference February 19, 2027 your attention Full-Year Results 23 | 17
Slide 18: Q&A
Q&A 24 | 18
Slide 19: Thank you for your attention
Siegfried | Thank you for your attention